Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Distinct immune "signatures" in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A ...

F5, Inc. today announced the appointment of two new members to its board of directors: Maya McReynolds, 53, and Julie Gonzalez, 43. Both joined F5's board effective October 10, 2024 and will serve on ...

Blackbaud , the leading provider of software for powering social impact, will report its third quarter 2024 financial results on Wednesday, October 30, before the U.S. financial markets open for ...

On Monday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $26.24 which represents a slight increase of $0.01 or 0.04% from the prior close of $26.23. The stock opened at $26.23 and ...

Distinct immune 'signatures' in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side ...

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...